Rash asociado a fármacos con eosinofilia y síntomas cutáneos. A propósito de un caso.
DOI:
https://doi.org/10.26871/killcanasalud.v7i1.1263Palabras clave:
Rash Cutaneo, Eosinofilia, Anticonvulsivantes, Reaccion Adversa a farmacosResumen
El Rash asociado a fármacos con eosinofilia y síntomas cutáneos conocido como síndrome DRESS, llamado por las iniciales inglesa, es una toxicodermia grave de etiología desconocida caracterizada por: fiebre, exantema, adenopatías, alteraciones hematológicas, afectación visceral y sistémica. Dada su gravedad y posible confusión con otras reacciones cutáneas medicamentosas, es importante establecer las relaciones causales y detectar los posibles fármacos implicados, además del diagnóstico diferencial por su compromiso dérmico y el tratamiento actualizado ante tal complicación.
El objetivo del presente artículo es describir un caso de Síndrome DRESS asociado a la administración de terapia anticonvulsivante que inicialmente se relacionó a una reacción de hipersensibilidad; el caso que se reporta es de una paciente de 36 años, atendida en consulta con tratamiento previo para Epilepsia, quien ingresa por reacción sistémica: compromiso dérmico, hepático y hematológico, esta patología fue tratada con terapia a base de corticoides, logrando la recidiva del cuadro clínico.
Descargas
Citas
OMS indicadores de farmacovigilancia: un manual práctico para la evaluación
de los sistemas de fármaco vigilancia [WHO pharmacovigilance indicators: a practical manual for the assessment of pharmacovigilance systems]. Ginebra: Organización Mundial de la Salud; 2019. Licencia: CC BY-NC-SA 3.0 IGO. https://apps.who.int/iris/bitstream/handle/10665/325851/9789243508252-spa.pdf?ua=1
Wolfson AR, Zhou L, Li Y, Phadke NA, Chow OA, BlumenthalKG. “Drug Reaction with eosinophilia and Systemic Symptoms (DRESS) Syndrome Identified in the electronic Health record Allergy Module”. J Allergy Clin Immunol Pract. 2019;7(2):633. DOI: 10.1016/j.jaip.2018.08.013
Muller P, Dubreil P, Mahé A, Lamaury I, Salzer B, Delomeauux J, StrobelM. “Drug Hypersensitivity Sindrome in a West Indian Population”. Eur J Dermatol 2003;13(5): 478. PMID: 14693494
Lee HY, Tay LK, Thirumoorthy T, Pang SM.” Cutaneous adverse drug reactions in hospitalised patients”. Singapore Med J 2010;51(10):767. PMID: 21103811
Fiszenson-Albala F, Auzerie V, Mahe E, Farinotti R, Durand-Stocco C, Crickx B, Descamps.” A 6-month prospective survey of cutaneous drug reactions in a hospital setting”Br J Dermatol. 2003;149(5):1018. DOI: 10.1111/j.1365-2133.2003.05584.x
Knowles SR, Shapiro LE, Shear NH.” Anticonvulsant hypersensitivity syndrome: incidence, prevention and management”. Drug Saf. 1999;21(6):489. DOI: 10.2165/00002018-199921060-00005
Kardaun SH, Sidoroff A, Valeyrie-Allanore L, et al. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist?. Br J Dermatol 2007; 156:609. DOI: 10.1111/j.1365-2133.2006.07704.x
Kardaun SH, Sekula P, Valeyrie-Allanore L, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol 2013; 169:1071. DOI: 10.1111/bjd.12501
Shiohara T, Mizukawa Y. Drug-induced hypersensitivity syndrome (DiHS)/drug reaction with eosinophilia and systemic symptoms (DRESS): An update in 2019. Allergol Int. 2019;68(3):301. Epub 2019 Apr 16. DOI: 10.1016/j.alit.2019.03.006
Morito H, Ogawa K, Fukumoto T, Kobayashi N, Morii T, Kasai T, Nonomura A, Kishimoto T, Asada H. I ncreased ratio of FoxP3+ regulatory T cells/CD3+ T cells in skin lesions in drug-induced hypersensitivity syndrome/drug rash with eosinophilia and systemic symptoms. Clin Exp Dermatol. 2014 Apr;39(3):284-91. DOI: 10.1111/ced.12246
Takahashi R, Kano Y, Yamazaki Y, Kimishima M, Mizukawa Y, Shiohara T. Defective regulatory T cells in patients with severe drug eruptions: timing of the dysfunction is associated with the pathological phenotype and outcome. J Immunol. 2009 Jun;182(12):8071-9. DOI: 10.4049/jimmunol.0804002
Husain Z, Reddy BY, Schwartz RA. DRESS syndrome: Part I. Clinical perspectives. J Am Acad Dermatol 2013; 68:693.e1. DOI: 10.1016/j.jaad.2013.01.032
Cacoub P, Musette P, Descamps V, et al. The DRESS syndrome: a literature review. Am J Med 2011; 124:588. DOI: 10.1016/j.amjmed.2011.01.017
Lam BD, Miller MM, Sutton AV, et al. Vancomycin and DRESS: A retrospective chart review of 32 cases in Los Angeles, California. J Am Acad Dermatol 2017; 77:973. DOI: 10.1016/j.jaad.2017.05.041
Coster A, Aerts O, Herman A, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome caused by first-line antituberculosis drugs: Two case reports and a review of the literature. Contact Dermatitis 2019; 81:325. DOI: 10.1111/cod.13296
Bourneau-Martin D, Leclech C, Jamet A, et al. Omeprazole-induced drug reaction with eosinophilia and systemic symptoms (DRESS). Eur J Dermatol 2014; 24:413. DOI: 10.1684/ejd.2014.2343
Peuvrel L, Quéreux G, Saint-Jean M, et al. Profile of vemurafenib-induced severe skin toxicities. J Eur Acad Dermatol Venereol 2016; 30:250. DOI: 10.1111/jdv.13443
Kim DK, Lee SW, Nam HS, et al. A Case of Sorafenib-induced DRESS Syndrome in Hepatocelluar Carcinoma. Korean J Gastroenterol 2016; 67:337. DOI: 10.4166/kjg.2016.67.6.337
Perry ME, Almaani N, Desai N, et al. Raltegravir-induced Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome - implications for clinical practice and patient safety. Int J STD AIDS 2013; 24:6. DOI: 10.1177/0956462413481528
Phillips EJ, Chung WH, Mockenhaupt M, Roujeau JC, Mallal SA. Drug hypersensitivity: pharmacogenetics and clinical syndromes. J Allergy Clin Immunol. 2011;127(3 Suppl): S60. DOI: 10.1016/j.jaci.2010.11.046
Cho YT, Yang CW, Chu CY. Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): An Interplay among Drugs, Viruses, and Immune System. Int J Mol Sci. 2017;18(6) Epub 2017 Jun 9. DOI: 10.3390/ijms18061243
Konvinse KC, Trubiano JA, Pavlos R, James I, Shaffer CM, Bejan CA, Schutte RJ, Ostrov DA, Pilkinton MA, Rosenbach M, Zwerner JP, Williams KB, Bourke J, Martinez P, Rwandamuriye F, Chopra A, Watson M, Redwood AJ, White KD, Mallal SA, Phillips EJ. HLA-A*32:01 is strongly associated with vancomycin-induced drug reaction with eosinophilia and systemic symptoms. J Allergy Clin Immunol. 2019 Jul;144(1):183-192. doi: 10.1016/j.jaci.2019.01.045. Epub 2019 Feb 16. PMID: 30776417; PMCID: PMC6612297.
Chen YC, Chiu HC, Chu CY. Drug reaction with eosinophilia and systemic symptoms: a retrospective study of 60 cases. Arch Dermatol. 2010 Dec;146(12):1373-9. Epub 2010 Aug 1. DOI: 10.1001/archdermatol.2010.198
Um SJ, Lee SK, Kim YH, et al. “Clinical Features of Drug-Induced Hypersensitivity Syndrome in 38 Patients. J Investig Allergol Clin Immunol 2010; 20: 556-562. PMID: 21313995
Tas S, Simonart T. “Management of Drug Rash with Eosinophilia and Systemic Symptoms (DRESS Syndrome): An Update”. Dermatology 2003; 206: 353-356. DOI: 10.1159/000069956
Natkunarajah J, Goolamali S, Craythorne E, Benton E, Smith C, Morris-Jones R, Wendon J, Higgins E, Creamer D. Ten cases of drug reaction with eosinophilia and systemic symptoms (DRESS) treated with pulsed intravenous methylprednisolone. Eur J Dermatol. 2011;21(3):385. DOI: 10.1684/ejd.2011.1300
Singer EM, Wanat KA, Rosenbach MA. A case of recalcitrant DRESS syndrome with multiple autoimmune sequelae treated with intravenous immunoglobulins. JAMA Dermatol. 2013 Apr;149(4):494-5. DOI: 10.1001/jamadermatol.2013.1949
Fields KS, Petersen MJ, Chiao E, Tristani-Firouzi P. Case reports: treatment of nevirapine-associated dress syndrome with intravenous immune globulin (IVIG). J Drugs Dermatol. 2005 Jul-Aug;4(4):510-3. PMID: 16004028.
Descargas
Publicado
- Resumen 45
- DESCARGAR PDF 31
